236 related articles for article (PubMed ID: 32606137)
1. Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition.
Cai SF; Chu SH; Goldberg AD; Parvin S; Koche RP; Glass JL; Stein EM; Tallman MS; Sen F; Famulare CA; Cusan M; Huang CH; Chen CW; Zou L; Cordner KB; DelGaudio NL; Durani V; Kini M; Rex M; Tian HS; Zuber J; Baslan T; Lowe SW; Rienhoff HY; Letai A; Levine RL; Armstrong SA
Cancer Discov; 2020 Oct; 10(10):1500-1513. PubMed ID: 32606137
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
3. Therapy Response and Outcome Explained by Leukemia Cell of Origin.
Gu Z; Dickerson KE; Xu J
Cancer Discov; 2020 Oct; 10(10):1445-1447. PubMed ID: 33004477
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
5. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
Cusan M; Cai SF; Mohammad HP; Krivtsov A; Chramiec A; Loizou E; Witkin MD; Smitheman KN; Tenen DG; Ye M; Will B; Steidl U; Kruger RG; Levine RL; Rienhoff HY; Koche RP; Armstrong SA
Blood; 2018 Apr; 131(15):1730-1742. PubMed ID: 29453291
[TBL] [Abstract][Full Text] [Related]
6. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
7. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.
Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD
Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation.
Wada T; Koyama D; Kikuchi J; Honda H; Furukawa Y
Blood; 2015 Jun; 125(24):3731-46. PubMed ID: 25904247
[TBL] [Abstract][Full Text] [Related]
9. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.
Krivtsov AV; Figueroa ME; Sinha AU; Stubbs MC; Feng Z; Valk PJ; Delwel R; Döhner K; Bullinger L; Kung AL; Melnick AM; Armstrong SA
Leukemia; 2013 Apr; 27(4):852-60. PubMed ID: 23235717
[TBL] [Abstract][Full Text] [Related]
10. Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition.
Abdel-Aziz AK; Pallavicini I; Ceccacci E; Meroni G; Saadeldin MK; Varasi M; Minucci S
Haematologica; 2020 Aug; 105(8):2105-2117. PubMed ID: 31537694
[TBL] [Abstract][Full Text] [Related]
11. Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.
Ravasio R; Ceccacci E; Nicosia L; Hosseini A; Rossi PL; Barozzi I; Fornasari L; Zuffo RD; Valente S; Fioravanti R; Mercurio C; Varasi M; Mattevi A; Mai A; Pavesi G; Bonaldi T; Minucci S
Sci Adv; 2020 Apr; 6(15):eaax2746. PubMed ID: 32284990
[TBL] [Abstract][Full Text] [Related]
12. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
Murray-Stewart T; Woster PM; Casero RA
Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
[TBL] [Abstract][Full Text] [Related]
13. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
14. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
15. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
16. Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis.
Kataoka K; Kurokawa M
Cancer Sci; 2012 Aug; 103(8):1371-7. PubMed ID: 22494115
[TBL] [Abstract][Full Text] [Related]
17. EVI1 induces autophagy to promote drug resistance via regulation of ATG7 expression in leukemia cells.
Niu Y; Yang X; Chen Y; Jin X; Li L; Guo Y; Li X; Xie Y; Zhang Y; Wang H
Carcinogenesis; 2020 Jul; 41(7):961-971. PubMed ID: 31593983
[TBL] [Abstract][Full Text] [Related]
18. Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion.
Pallavi R; Gatti E; Durfort T; Stendardo M; Ravasio R; Leonardi T; Falvo P; Duso BA; Punzi S; Xieraili A; Polazzi A; Verrelli D; Trastulli D; Ronzoni S; Frascolla S; Perticari G; Elgendy M; Varasi M; Colombo E; Giorgio M; Lanfrancone L; Minucci S; Mazzarella L; Pelicci PG
Nat Commun; 2024 Jan; 15(1):828. PubMed ID: 38280853
[TBL] [Abstract][Full Text] [Related]
19. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
[TBL] [Abstract][Full Text] [Related]
20. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
Barth J; Abou-El-Ardat K; Dalic D; Kurrle N; Maier AM; Mohr S; Schütte J; Vassen L; Greve G; Schulz-Fincke J; Schmitt M; Tosic M; Metzger E; Bug G; Khandanpour C; Wagner SA; Lübbert M; Jung M; Serve H; Schüle R; Berg T
Leukemia; 2019 Jun; 33(6):1411-1426. PubMed ID: 30679800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]